Analyzing Sinovac Biotech (SVA) and Catalyst Biosciences (CBIO)

Sinovac Biotech (NASDAQ: SVA) and Catalyst Biosciences (NASDAQ:CBIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Volatility & Risk

Sinovac Biotech has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, Catalyst Biosciences has a beta of 2.68, indicating that its share price is 168% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Sinovac Biotech and Catalyst Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sinovac Biotech 0 0 0 0 N/A
Catalyst Biosciences 0 0 3 0 3.00

Catalyst Biosciences has a consensus price target of $13.33, indicating a potential downside of 47.24%. Given Catalyst Biosciences’ higher possible upside, analysts clearly believe Catalyst Biosciences is more favorable than Sinovac Biotech.

Institutional & Insider Ownership

31.8% of Sinovac Biotech shares are held by institutional investors. Comparatively, 23.0% of Catalyst Biosciences shares are held by institutional investors. 5.0% of Catalyst Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Sinovac Biotech and Catalyst Biosciences’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sinovac Biotech $72.43 million 6.64 -$590,000.00 ($0.01) -843.16
Catalyst Biosciences $400,000.00 367.05 -$16.94 million ($13.12) -1.93

Sinovac Biotech has higher revenue and earnings than Catalyst Biosciences. Sinovac Biotech is trading at a lower price-to-earnings ratio than Catalyst Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sinovac Biotech and Catalyst Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sinovac Biotech N/A N/A N/A
Catalyst Biosciences -2,438.50% -91.67% -55.28%

Summary

Sinovac Biotech beats Catalyst Biosciences on 7 of the 13 factors compared between the two stocks.

Sinovac Biotech Company Profile

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company’s pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply